PATENT 2870-0263P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Rintaro YAMADA et al. Conf.: UNKNOWN

Appl. No.: 10/623,751 Group: UNKNOWN

Filed: July 22, 2003 Examiner: UNKNOWN

For: 5-SUBSTITUTED ISOQUINOLINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

OCT 1 0 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. This application was filed before June 30, 2003.

 Accordingly, submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. This application was filed on or after June 30, 2003. Accordingly, copies of cited U.S. patents and patent application publications therefore are not included. Copies of foreign patent documents and non-patent literature are included.

c. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. \square DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. \boxtimes OTHER

The following additional information is provided for the Examiner's consideration.

Patent Family information is provided for some of the U.S. Patents and foreign references listed on the PTO-1449 Form.

English abstracts are provided for each non-English language reference.

EP 0 966 436 B1 corresponds to U.S. Patent 6,262,112.

WO 99/43647 corresponds to U.S. Patent Nos. 6,281,243 and 6,403,573.

WO 00/27819 corresponds to CA 2 350 208. $\underline{\text{FEES}}$

IV.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b):			
	a.	\boxtimes	within three months of the filing date of a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's.)			
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or statement is required.			
	C.		concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.			
	d.		before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge our deposit account in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).			
V.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): ck one box)			
	C.F.I	before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)).				
	a.		No statement; therefore, a fee in the amount of $\frac{180.00}{\text{or}}$ as required by 37 C.F.R. § 1.17(p).			
	b.		See the statement below. No fee is required.			

STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) VI. The undersigned hereby states that each item of information contained in the IDS was a. first cited in any communication from a foreign Office in counterpart Patent а application not more than three months prior to the filing of this IDS; or no item of information contained in the IDS was b. cited in a communication from a foreign Patent Office in a counterpart foreign application, and, the knowledge of the person signing the certification after making reasonable inquiry, no individual item of IDS was known to any designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a c. communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Office counterpart Patent in a application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VII. PAYMENT OF FEES (check one box) A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee. Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the aboveindicated fee. A triplicate copy of this paper is attached.

 \boxtimes

No fee is required.

Appl. No. 10/623,751

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Ynge Car (2 Bo40, 664)
Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/las 2870-0263P

Attachment(s):	\boxtimes	PTO-1449
	\boxtimes	Documents
		Foreign Search Report
		Fee
		Other:

(Rev. 09/30/03)

APPLICATION NO. ATTY. DOCKET NO. Form PTO-1449 10/623,751 2870-0263P INFORMATION DISCLOSURE CITATION APPLICANT Rintaro YAMADA et al. IN AN APPLICATION GROUP (Use several sheets if necessar FILING DATE July 22, 2003 Unknown TEMPEN DOCUMENTS CLASS EXAMINER INITIAL DATE NAME DOCUMENT NUMBER Kind Leysen et al. US 6,281,243 B1 2001-08-28 US 6,403,573 B1 2002-06-11 Leysen et al. Campbell et al. US 4,520,025 1985-05-28 US 4,473,501 1984-09-25 Lowrie US 2003/0004158 2003-01-02 Scarborough et al. **A1** US 5,362,878 1994-11-08 Chang et al. Α US 5,656,634 1997-08-12 Chang et al. Α US 4,798,897 Hidaka et al. 1989-01-17 Hidaka et al. US 6,153,608 2000-11-28 Α Mittendorf et al. US 6,262,112 2001-07-17 B1 FOREIGN PATENT DOCUMENTS RANSLATION/ ABSTRACT DATE COUNTRY CLASS SUB CLASS Office DOCUMENT Kind YES NUMBER 2002-11-13 EUROPE 1 256 574 A1 EP 1 065 200 A1 2001-01-03 **EUROPE** ΕP X JP 10-87629 Α 1998-04-07 JAPAN X EUROPE EΡ 0 966 436 B1 2002-12-11 WIPO 93/15073 1993-08-05 WO Α1 WIPO Х WO 00/27819 A2 2000-03-18 CA 2 350 208 A1 2000-05-18 CANADA JAPAN Х JΡ 3408546 B2 2003-03-14 EUROPE 0 061 673 1984-10-24 EΡ B1 1999-04-29 WIPO X 99/20620 A1 WO 1999-11-17 EUROPE 0 956 865 A1 EP 99/43647 1999-09-02 WIPO WO Α1 OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Suzuki et al., Br. J. Pharmacol. (1993), 109, 703-712 P. H. Howe et al., Biochem J. (1988) 255, 423-429 P. L. Mobley, Experimental Cell Research, 214, 55-66 (1994) EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.